334 related articles for article (PubMed ID: 33445545)
1. Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery.
Khiev D; Mohamed ZA; Vichare R; Paulson R; Bhatia S; Mohapatra S; Lobo GP; Valapala M; Kerur N; Passaglia CL; Mohapatra SS; Biswal MR
Nanomaterials (Basel); 2021 Jan; 11(1):. PubMed ID: 33445545
[TBL] [Abstract][Full Text] [Related]
2. Recent patents on ophthalmic nanoformulations and therapeutic implications.
Ako-Adounvo AM; Nagarwal RC; Oliveira L; Boddu SH; Wang XS; Dey S; Karla PK
Recent Pat Drug Deliv Formul; 2014; 8(3):193-201. PubMed ID: 25262835
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
[TBL] [Abstract][Full Text] [Related]
4. Therapeutics and carriers: the dual role of proteins in nanoparticles for ocular delivery.
Pescina S; Sonvico F; Santi P; Nicoli S
Curr Top Med Chem; 2015; 15(4):369-85. PubMed ID: 25579343
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in topical nano drug-delivery systems for the anterior ocular segment.
Lakhani P; Patil A; Majumdar S
Ther Deliv; 2018 Feb; 9(2):137-153. PubMed ID: 29325511
[TBL] [Abstract][Full Text] [Related]
6. Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective.
Zhang J; Jiao J; Niu M; Gao X; Zhang G; Yu H; Yang X; Liu L
Int J Nanomedicine; 2021; 16():6497-6530. PubMed ID: 34588777
[TBL] [Abstract][Full Text] [Related]
7. Recent Developments of Nanostructures for the Ocular Delivery of Natural Compounds.
Razavi MS; Ebrahimnejad P; Fatahi Y; D'Emanuele A; Dinarvand R
Front Chem; 2022; 10():850757. PubMed ID: 35494641
[TBL] [Abstract][Full Text] [Related]
8. Current Advances in Nano-Based and Polymeric Stimuli-Responsive Drug Delivery Targeting the Ocular Microenvironment: A Review and Envisaged Future Perspectives.
Dludla SBK; Mashabela LT; Ng'andwe B; Makoni PA; Witika BA
Polymers (Basel); 2022 Aug; 14(17):. PubMed ID: 36080651
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnology-based ocular drug delivery systems: recent advances and future prospects.
Li S; Chen L; Fu Y
J Nanobiotechnology; 2023 Jul; 21(1):232. PubMed ID: 37480102
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnology-based formulations to amplify intraocular bioavailability.
Kagkelaris K; Panayiotakopoulos G; Georgakopoulos CD
Ther Adv Ophthalmol; 2022; 14():25158414221112356. PubMed ID: 35873277
[TBL] [Abstract][Full Text] [Related]
11. Fundamentals, challenges, and nanomedicine-based solutions for ocular diseases.
Srinivasarao DA; Lohiya G; Katti DS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jul; 11(4):e1548. PubMed ID: 30506871
[TBL] [Abstract][Full Text] [Related]
12. Nanocrystal for ocular drug delivery: hope or hype.
Sharma OP; Patel V; Mehta T
Drug Deliv Transl Res; 2016 Aug; 6(4):399-413. PubMed ID: 27165145
[TBL] [Abstract][Full Text] [Related]
13. Ocular novel drug delivery: impacts of membranes and barriers.
Barar J; Javadzadeh AR; Omidi Y
Expert Opin Drug Deliv; 2008 May; 5(5):567-81. PubMed ID: 18491982
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticulate-based drug delivery systems for small molecule anti-diabetic drugs: An emerging paradigm for effective therapy.
Uppal S; Italiya KS; Chitkara D; Mittal A
Acta Biomater; 2018 Nov; 81():20-42. PubMed ID: 30268916
[TBL] [Abstract][Full Text] [Related]
15. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits.
Chetoni P; Burgalassi S; Monti D; Tampucci S; Tullio V; Cuffini AM; Muntoni E; Spagnolo R; Zara GP; Cavalli R
Eur J Pharm Biopharm; 2016 Dec; 109():214-223. PubMed ID: 27789355
[TBL] [Abstract][Full Text] [Related]
16. The prominence of the dosage form design to treat ocular diseases.
Campos PM; Petrilli R; Lopez RFV
Int J Pharm; 2020 Aug; 586():119577. PubMed ID: 32622806
[TBL] [Abstract][Full Text] [Related]
17. Ocular drug delivery systems: An overview.
Patel A; Cholkar K; Agrahari V; Mitra AK
World J Pharmacol; 2013; 2(2):47-64. PubMed ID: 25590022
[TBL] [Abstract][Full Text] [Related]
18. Nanoscale delivery systems in treatment of posterior ocular neovascularization: strategies and potential applications.
Bhatt P; Kelly S; Sutariya V
Ther Deliv; 2019 Nov; 10(11):737-747. PubMed ID: 31718481
[TBL] [Abstract][Full Text] [Related]
19. Liposomes and nanotechnology in drug development: focus on ocular targets.
Honda M; Asai T; Oku N; Araki Y; Tanaka M; Ebihara N
Int J Nanomedicine; 2013; 8():495-503. PubMed ID: 23439842
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicines for the treatment of glaucoma: Current status and future perspectives.
Zhai Z; Cheng Y; Hong J
Acta Biomater; 2021 Apr; 125():41-56. PubMed ID: 33601065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
